Innate Immunotherapeutics Limited is engaged in research and development of its lead drug candidate (MIS416) to treat secondary progressive multiple sclerosis (SPMS). The Company has designed and manufactured an immunomodulator micro particle technology. Its drug candidate, MIS416, is a construct of the micro particle and naturally occurring, non-immunogenic, cytosolically active Toll-like receptors 9 (TLR-9) and Nucleotide-binding oligomerization domain-containing protein 2 (NOD-2) ligands. MIS416 has specific immunomodulatory effects on dendritic cell, monocyte and macrophage, Natural Killer (NK) and Natural killer T (NKT) cell cytokine secretion patterns, in parallel with enhancement of a range of soluble and cellular tumouricidal mechanisms, such as granule, Fas, tumor necrosis factor alpha (TNF-a) and TNF related apoptosis-inducing ligand (TRAIL). The Company has completed Phase IIA dose confirmation trial of MIS416 in patients with secondary progressive multiple sclerosis.